COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.
Identifieur interne : 000540 ( Main/Exploration ); précédent : 000539; suivant : 000541COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.
Auteurs : Kam Wa Chan [Hong Kong] ; Vivian Taam Wong [Hong Kong] ; Sydney Chi Wai Tang [Hong Kong]Source :
- The American journal of Chinese medicine [ 1793-6853 ] ; 2020.
Abstract
As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.
DOI: 10.1142/S0192415X20500378
PubMed: 32164424
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000072
- to stream PubMed, to step Curation: 000072
- to stream PubMed, to step Checkpoint: 000509
- to stream Ncbi, to step Merge: 000D52
- to stream Ncbi, to step Curation: 000D52
- to stream Ncbi, to step Checkpoint: 000D52
- to stream Main, to step Merge: 000542
- to stream Main, to step Curation: 000540
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.</title><author><name sortKey="Chan, Kam Wa" sort="Chan, Kam Wa" uniqKey="Chan K" first="Kam Wa" last="Chan">Kam Wa Chan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, The University of Hong Kong, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine, The University of Hong Kong</wicri:regionArea><wicri:noRegion>The University of Hong Kong</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Vivian Taam" sort="Wong, Vivian Taam" uniqKey="Wong V" first="Vivian Taam" last="Wong">Vivian Taam Wong</name><affiliation wicri:level="1"><nlm:affiliation>School of Chinese Medicine The University of Hong Kong, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>School of Chinese Medicine The University of Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Tang, Sydney Chi Wai" sort="Tang, Sydney Chi Wai" uniqKey="Tang S" first="Sydney Chi Wai" last="Tang">Sydney Chi Wai Tang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, The University of Hong Kong, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine, The University of Hong Kong</wicri:regionArea><wicri:noRegion>The University of Hong Kong</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32164424</idno><idno type="pmid">32164424</idno><idno type="doi">10.1142/S0192415X20500378</idno><idno type="wicri:Area/PubMed/Corpus">000072</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000072</idno><idno type="wicri:Area/PubMed/Curation">000072</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000072</idno><idno type="wicri:Area/PubMed/Checkpoint">000509</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000509</idno><idno type="wicri:Area/Ncbi/Merge">000D52</idno><idno type="wicri:Area/Ncbi/Curation">000D52</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D52</idno><idno type="wicri:Area/Main/Merge">000542</idno><idno type="wicri:Area/Main/Curation">000540</idno><idno type="wicri:Area/Main/Exploration">000540</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.</title><author><name sortKey="Chan, Kam Wa" sort="Chan, Kam Wa" uniqKey="Chan K" first="Kam Wa" last="Chan">Kam Wa Chan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, The University of Hong Kong, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine, The University of Hong Kong</wicri:regionArea><wicri:noRegion>The University of Hong Kong</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Vivian Taam" sort="Wong, Vivian Taam" uniqKey="Wong V" first="Vivian Taam" last="Wong">Vivian Taam Wong</name><affiliation wicri:level="1"><nlm:affiliation>School of Chinese Medicine The University of Hong Kong, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>School of Chinese Medicine The University of Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Tang, Sydney Chi Wai" sort="Tang, Sydney Chi Wai" uniqKey="Tang S" first="Sydney Chi Wai" last="Tang">Sydney Chi Wai Tang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, The University of Hong Kong, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine, The University of Hong Kong</wicri:regionArea><wicri:noRegion>The University of Hong Kong</wicri:noRegion></affiliation></author></analytic><series><title level="j">The American journal of Chinese medicine</title><idno type="eISSN">1793-6853</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest <i>in silico</i> findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.</div></front></TEI><affiliations><list><country><li>Hong Kong</li></country></list><tree><country name="Hong Kong"><noRegion><name sortKey="Chan, Kam Wa" sort="Chan, Kam Wa" uniqKey="Chan K" first="Kam Wa" last="Chan">Kam Wa Chan</name></noRegion><name sortKey="Tang, Sydney Chi Wai" sort="Tang, Sydney Chi Wai" uniqKey="Tang S" first="Sydney Chi Wai" last="Tang">Sydney Chi Wai Tang</name><name sortKey="Wong, Vivian Taam" sort="Wong, Vivian Taam" uniqKey="Wong V" first="Vivian Taam" last="Wong">Vivian Taam Wong</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000540 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000540 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32164424
|texte= COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32164424" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |